Table 3 Novel preparations of mineral drugs and preclinical study
From: Mineral medicine: from traditional drugs to multifunctional delivery systems
Register number | Study title | Conditions | Interventions/drugs | Locations |
|---|---|---|---|---|
NCT04687176 | Frontline oral arsenic trioxide for APL | APL | Dru: oral arsenic trioxide formulation | The University of Hong Kong |
NCT03624270 | Oral arsenic trioxide for newly diagnosed acute promyelocytic | APL | Drug: oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid | The University of Hong Kong |
NCT04689815 | Oral arsenic trioxide for nucleophosmin 1 mutated acute myeloid leukemia (AML) | AML | Drug: oral arsenic trioxide formulation | The University of Hong Kong |
NCT04634838 | Efficacy dressings with copper oxide | Pressure ulcer | Device: medcu antibacterial wound dressings with copper oxide | Loewenstein Rehabilitation Center ra'anana, Israel |
NCT01565798 | Efficacy of copper to reduce acquisition of microbes and healthcare-acquired infections | Healthcare-acquired infection | Other: copper-alloy surfaced patient care objects | Medical University of South Carolina |
NCT01678612 | Efficacy of copper in reducing health-acquired infections in a pediatric intensive care unit | Nosocomial infections | Copper-alloy surfaced objects | Hospital Roberto del Rio, Santiago, Chile |
NCT03323346 | Phase II trial of disulfiram with copper in metastatic breast cancer | Breast neoplasm female | Drug: disulfiram | University hospital Olomouc, Olomouc, Czechia |
NCT03284749 | Effect of copper on the healing of obstetric wounds | Cesarean section and infection | Other: copper impregnated wound dressing, and normal wound dressing | Croydon health services NHS trust |
NCT04511468 | Zinc, chromium, vitamin C, and copper combination supplement for prediabetes progression | Prediabetes | Dietary supplement: zinc, chromium, vitamin C, and copper supplementation, and placebo | Human Nutrition Research Center |
NCT01777919 | Disulfiram/copper combination in the treatment of newly diagnosed glioblastoma multiform | Glioblastoma multiforme | Temozolomide, disulfiram, copper | Olympion medical Center, Patras, Greece |
NCT00608946 | Treatment with copper in patients with mild Alzheimer’s dementia | Alzheimer’s disease | Dietary supplement: copper |  |
NCT03736109 | Role of a copper-albumin complex in the treatment of knee osteoarthritis in human | Osteo arthritis knee | Genetic: soluble and genetic biomarkers measurements |  |
NCT02715609 | Disulfiram/copper with concurrent radiation therapy and temozolomide in patients with newly diagnosed glioblastoma | Glioblastoma multiforme | Drug: disulfiram, and copper gluconate | Washington University school of medicine, Saint Louis, Missouri, United States |
NCT01017315 | Efficacy of baby talcum in the prevention of pruritus assosiated with cast | Fracture distal radius | Drug: baby talcum | Prince of Songkhla university |
NCT04792970 | Randomized controlled trial of talc instillation in addition to daily drainage through a tunneled pleural catheter to improve rates of outpatient pleurodesis in patients with malignant pleural | Malignant pleural effusion | Drug: talc | Duke University Medical center, Durham, North Carolina, United States |
NCT00789087 | Talc pleurodesis in patients with recurrent malignant pleural effusion | Recurrent malignant pleural effusion | Procedure: video thoracoscopic talc poudrage, and talc slurry through a chest tube | University of são Paulo medical school |
NCT03635138 | Effect of the incoportation of copper and zinc nanoparticles into dental adhesives | Caries, dental | Other: metal nanoparticles (Zn and Cu), and dental adhesive pure | Eduardo Fernández G, Santiago, Metropolitana |
NCT04775238 | Effect of metallic nanoparticles on nosocomial bacteria | Nosocomial infections | Other: silver nanoparticles, and copper nanoparticles | Faculty of medicine-sohag University, Sohag, Egypt |
NCT02200978 | A study for improving the outcome of childhood acute promyeloid leukemia | Childhood acute promyelocytic leukemia | Drug: indigo naturalis formula, and ATO, ATRA (and 5 more…) | The first affiliated hospital of Sun Yat-Sen University |
NCT04489706 | Arsenic trioxide in recurrent and metastatic ovarian cancer and endometrial cancer with P53 mutation | Ovarian cancer | Drug: arsenic trioxide for injection | Shanghai Jiaotong university school of medicine affliated ruijin hospital |
NCT02966301 | Treatment of chronic graft versus host disease with arsenic trioxide | Chronic graft-versus-host disease | Drug: arsenic trioxide injectable solution | CHU de caen-institut d'Hématologie de basse normandie |
NCT01470248 | Study of arsenic trioxide in small cell lung cancer | Lung cancer | Drug: arsenic trioxide | Emory University Winship Cancer institute |
NCT01791894 | Arsenic trioxide in treating patients with basal cell carcinoma | Basal cell carcinoma of the skin | Drug: arsenic trioxide | Stanford university medical center |
NCT03751917 | Long-term safety study of arsenic trioxide in newly diagnosed, low-to-intermediate risk acute promyelocytic leukemia | Acute promyelocytic leukemia | Drug: Arsenic Trioxide | Aon Ss. Antonio E Biagio E C. Arrigo-Alessandria-soc ematologia,Alessandria, Italy |
NCT00009867 | Arsenic trioxide in treating patients with urothelial cancer | Recurrent transitional cell cancer of the renal pelvis and ureter | Drug: arsenic trioxide | Cancer and leukemia group B |
NCT00024258 | Arsenic trioxide in treating patients with advanced neuroblastoma or other childhood solid tumors | Brain and central nervous system tumors | Drug: arsenic trioxide | Memorial Sloan-Kettering Cancer Center, New York |
NCT00008697 | Arsenic trioxide in treating patients with refractory or recurrent acute promyelocytic leukemia | Leukemia | Drug: arsenic trioxide | Washington university school of medicine |
NCT00045565 | Arsenic trioxide plus radiation therapy in treating patients with newly diagnosed malignant glioma | Adult giant cell glioblastoma | Drug: arsenic trioxide | New approaches to brain tumor therapy consortium, Baltimore |
NCT00517712 | Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia | Acute promyelocytic leukemia | Drug: single-agent arsenic trioxide | Kidwai memorial institute of oncology, India |
NCT00053222 | Arsenic trioxide in treating patients with pancreatic cancer that has not responded to gemcitabine | Pancreatic cancer | Drug: arsenic trioxide | Decatur memorial hospital cancer care institute, Decatur, Illinois, United States |
NCT00193518 | Arsenic trioxide in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma | Chronic lymphocytic leukemia | Drug: arsenic trioxide | Tennessee Oncology, Nashville, Tennessee, United States |
NCT00128596 | Arsenic trioxide in treating patients with metastatic liver cancer that cannot be removed by surgery | Liver cancer | Drug: arsenic trioxide | UPMC cancer centers, Pittsburgh, Pennsylvania, United States |
NCT00003630 | Arsenic trioxide in treating patients with advanced solid tumors | Unspecified adult solid tumor, protocol-specific | Drug: arsenic trioxide | Memorial Sloan-Kettering cancer center, New York |
NCT00075426 | Arsenic trioxide in treating patients with locally advanced or metastatic non-small cell lung cancer | Lung cancer | Drug: arsenic trioxide | University of texas medical branch |
NCT00005069 | Arsenic trioxide in treating patients with metastatic kidney cancer | Kidney cancer | Drug: arsenic trioxide | Memorial Sloan-Kettering cancer center New York |
NCT00005040 | Arsenic trioxide in treating patients with relapsed or refractory non-Hodgkin's lymphoma | Lymphoma | Drug: arsenic trioxide | Memorial Sloan-Kettering cancer center New York |
NCT00036842 | Arsenic trioxide in treating men with germ cell cancer | Extragonadal germ cell tumor testicular germ cell tumor | Drug: arsenic trioxide | MBCCOP-Gulf coast mobile, Alabama, United States |
NCT03503864 | Phase II study of combined chemotherapy with arsenic trioxide in stage 4/M neuroblastoma | Neuroblastoma | Drug: arsenic trioxide | Sun Yat-sen memorial hospital, Sun Yat-sen University |
NCT04869475 | Arsenic trioxide in refractory solid tumors with rescuable p53 mutation | Refractory solid tumors | Drug: arsenic trioxide | Department of Oncology, Ruijin hospital |
NCT00621023 | Cephalon decitabine, arsenic trioxide, and ascorbic acid for myelodysplastic syndrome | Myelodysplastic syndrome | Drug: decitabine, arsenic trioxide, and ascorbic acid | Duke university medical center |